“

Nevertheless, there was no evidence (to suggest) that those people over 65 were not getting evidence of efficacy, since then we’ve seen more data coming through from AstraZeneca as more people are completing the trial, which highlights again that efficacy in the elderly is seen, and there’s no evidence of lack of efficacy.